ClinicalTrials.gg
CompletedNCT01849289BEGIN™Updated Apr 7, 2017Results posted

A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes

A Phase 3 interventional study of Insulin Degludec and Insulin Glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 81 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-07.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
833
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.

Enrollment
6th of 70
833 · median 384
Started
2013
with 7 others
Phase 3
49 of 70
2 open now
Registered
34th of 70
by date
Lead sponsor
56 of 70
Novo Nordisk A/S

Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 6th largest by enrollment, is one of 8 that started in 2013, is one of 49 in phase 3, and was the 34th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About insulin degludec

insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial was conducted in Africa, Asia, Europe, North and South America. The aim of the trial was to compare efficacy and safety of insulin degludec and insulin glargine in insulin naïve subjects with type 2 diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 833 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months
  • Insulin naïve subjects (Allowed are: previous short term insulin treatment up to 14 days; treatment during hospitalisation or during gestational diabetes is allowed for periods longer than 14 days)
  • Current treatment: metformin monotherapy or metformin in any combination with an insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase IV (DPP-IV) inhibitor, alfa-glucosidase-inhibitors (acarbose) with unchanged dosing for at least 3 months prior to randomisation (Visit 2) with the minimum doses stated: metformin: alone or in combination (including fixed combination) 1500 mg daily, or maximum tolerated dose (at least 1000 mg daily), insulin secretagogue (sulfonylurea or glinide): minimum half of the daily maximal dose according to local labelling, DPP-IV inhibitor: minimum 100 mg daily or according to local labelling, alfa-glucosidase-inhibitors (acarbose): minimum half of the daily maximal dose or maximum tolerated dose
  • (glycosylated ) 7.0-10.0% (both inclusive) by central laboratory analysis
  • (Body Mass Index) below or equal to 40.0 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Treatment with TZDs (thiazoledinedione), or GLP-1 (glucagon-like peptide 1) receptor agonists within the last 3 months prior to Visit 1 (screening)
  • Anticipated change in concomitant medication known to interfere significantly with glucose metabolism, such as systemic , beta-blockers, MAO (monoamine oxidase) inhibitors
  • Cardiovascular disease within the last 6 months prior to Visit 1 (screening) defined as stroke; decompensated heart failure (New York Heart Association) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty
  • Any disease or disorder, except for conditions associated with type 2 diabetes mellitus, which in the Investigator's opinion could interfere with the results of the trial
  • Previous participation in this trial. Participation is defined as randomised. Re-screening of screening failures is allowed only once within the limits of the recruitment period
  • Known or suspected to trial product(s) or related products
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
833 participants (actual)

Study arms

  • Experimental
    Insulin Degludec

    Drug: Insulin Degludec

  • Experimental
    Insulin Glargine

    Drug: Insulin Glargine

Interventions

  • Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.

    Also known as: NN1250

  • Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c (%) (Analysed by Central Laboratory)

    Change from baseline in HbA1c (%) after 26 weeks of treatment.

    Time frame: Week 0, week 26

Secondary outcomes

  1. Number of Severe and Minor Treatment Emergent Hypoglycaemic Episodes

    Confirmed hypoglycaemic episodes consisted of episodes of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed PG value of less than 3.1 mmol/L (56 mg/dL).Minor hypoglycaemic episode is defined as an episode with symptoms consistent with hypoglycaemia with confirmation by full blood glucose \< 2.8 mmol/L (50 mg/dL), or PG \< 3.1 mmol/L (56 mg/dL) and which is handled by the subject himself/herself or any asymptomatic full blood glucose value \< 2.8 mmol/L (50 mg/dL) or PG value \< 3.1 mmol/L (56 mg/dL).

    Time frame: On or after the first day of exposure to randomised trial drug (week 0) and no later than 7 days after last exposure to randomised trial drug (week 27)

  2. Change From Baseline in FPG (Fasting Plasma Glucose) (Analysed by Central Laboratory)

    Change from baseline in FPG after 26 weeks of treatment.

    Time frame: Week 0, week 26

  3. Within-subject Variability as Measured by Coefficient of Variation (CV%) in Pre-breakfast SMPG (Self-measured Plasma Glucose)

    Within subject Coefficient of variation(CV\[%\]) in pre-breakfast self measured plasma glucose for dose adjustment after 26 treatment weeks are displayed below.

    Time frame: Week 26

  4. Responder for HbA1c (Below 7.0%) at End of Trial Without Severe and Minor Hypoglycaemic Episodes

    A responder for HbA1c without severe or confirmed hypoglycaemia is defined as a subject, who meets the HbA1c target at end of trial without treatment emergent severe or confirmed hypoglycaemia during the last 12 weeks of treatment or within 7 days from last treatment.

    Time frame: Week 26

  5. Number of Treatment Emergent AEs (Adverse Events)

    Treatment emergent events (after first trial product administration and no later than 7 days after last trial product administration)

    Time frame: On or after the first day of exposure to randomised trial drug (week 0) and no later than seven days after last exposure to randomised trial drug (week 27)

08

Results

Posted Jan 14, 2016

Participant flow

The trial was conducted at 68 sites in six countries as follows: Brazil: 3 sites; Canada: 7 sites; China: 37 sites; South Africa: 4 sites; Ukraine: 6 sites; United States: 11 sites.

Participant flow — Overall Study
MilestoneIDeg ODIGlar OD
Started555278
Exposed553278
Completed523254
Not completed3224
Withdrew: Adverse event33
Withdrew: Protocol violation33
Withdrew: Withdrawal criteria10
Withdrew: Unclassified2518

Outcome measures

PrimaryChange From Baseline in HbA1c (%) (Analysed by Central Laboratory)

Change from baseline in HbA1c (%) after 26 weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · percentage of glycosylated haemoglobin
Change From Baseline in HbA1c (%) (Analysed by Central Laboratory)
percentage of glycosylated haemoglobinIDeg ODIGlar OD
Change From Baseline in HbA1c (%) (Analysed by Central Laboratory)-1.3 ± 1.1-1.2 ± 1.0
SecondaryNumber of Severe and Minor Treatment Emergent Hypoglycaemic Episodes

Confirmed hypoglycaemic episodes consisted of episodes of severe hypoglycaemia as well as minor hypoglycaemic episodes with a confirmed PG value of less than 3.1 mmol/L (56 mg/dL).Minor hypoglycaemic episode is defined as an episode with symptoms consistent with hypoglycaemia with confirmation by full blood glucose \< 2.8 mmol/L (50 mg/dL), or PG \< 3.1 mmol/L (56 mg/dL) and which is handled by the subject himself/herself or any asymptomatic full blood glucose value \< 2.8 mmol/L (50 mg/dL) or PG value \< 3.1 mmol/L (56 mg/dL).

Time frame:
On or after the first day of exposure to randomised trial drug (week 0) and no later than 7 days after last exposure to randomised trial drug (week 27)
Reported as:
Number · Episodes/100 years of patient exposure
Number of Severe and Minor Treatment Emergent Hypoglycaemic Episodes
Episodes/100 years of patient exposureIDeg ODIGlar OD
Number of Severe and Minor Treatment Emergent Hypoglycaemic Episodes8597
SecondaryChange From Baseline in FPG (Fasting Plasma Glucose) (Analysed by Central Laboratory)

Change from baseline in FPG after 26 weeks of treatment.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change From Baseline in FPG (Fasting Plasma Glucose) (Analysed by Central Laboratory)
mmol/LIDeg ODIGlar OD
Change From Baseline in FPG (Fasting Plasma Glucose) (Analysed by Central Laboratory)-3.35 ± 2.91-3.14 ± 2.71
SecondaryWithin-subject Variability as Measured by Coefficient of Variation (CV%) in Pre-breakfast SMPG (Self-measured Plasma Glucose)

Within subject Coefficient of variation(CV\[%\]) in pre-breakfast self measured plasma glucose for dose adjustment after 26 treatment weeks are displayed below.

Time frame:
Week 26
Reported as:
Mean · percentage
Within-subject Variability as Measured by Coefficient of Variation (CV%) in Pre-breakfast SMPG (Self-measured Plasma Glucose)
percentageIDeg ODIGlar OD
Within-subject Variability as Measured by Coefficient of Variation (CV%) in Pre-breakfast SMPG (Self-measured Plasma Glucose)10.65 ± 9.1510.01 ± 7.95
SecondaryResponder for HbA1c (Below 7.0%) at End of Trial Without Severe and Minor Hypoglycaemic Episodes

A responder for HbA1c without severe or confirmed hypoglycaemia is defined as a subject, who meets the HbA1c target at end of trial without treatment emergent severe or confirmed hypoglycaemia during the last 12 weeks of treatment or within 7 days from last treatment.

Time frame:
Week 26
Reported as:
Number · participants
Responder for HbA1c (Below 7.0%) at End of Trial Without Severe and Minor Hypoglycaemic Episodes
participantsIDeg ODIGlar OD
Responder for HbA1c (Below 7.0%) at End of Trial Without Severe and Minor Hypoglycaemic Episodes252114
SecondaryNumber of Treatment Emergent AEs (Adverse Events)

Treatment emergent events (after first trial product administration and no later than 7 days after last trial product administration)

Time frame:
On or after the first day of exposure to randomised trial drug (week 0) and no later than seven days after last exposure to randomised trial drug (week 27)
Reported as:
Number · number of events
Number of Treatment Emergent AEs (Adverse Events)
number of eventsIDeg ODIGlar OD
Number of Treatment Emergent AEs (Adverse Events)612387

Adverse events

Collected over Treatment emergent events (after first trial product administration and no later than 7 days after last trial product administration). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDeg OD—16/553 (2.9%)100/553 (18.1%)
IGlar OD—10/278 (3.6%)58/278 (20.9%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventIDeg ODIGlar OD
HypoglycaemiaMetabolism and nutrition disorders1/5532/278
Cerebral infarctionNervous system disorders2/5531/278
Cerebrovascular accidentNervous system disorders2/5530/278
Coronary artery stenosisCardiac disorders0/5531/278
PalpitationsCardiac disorders0/5531/278
Crohn's diseaseGastrointestinal disorders0/5531/278
AppendicitisInfections and infestations1/5531/278
Herpes zoster disseminatedInfections and infestations0/5531/278
PneumoniaInfections and infestations0/5531/278
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5531/278
Most frequent other events
Most frequent other events
EventIDeg ODIGlar OD
Upper respiratory tract infectionInfections and infestations60/55332/278
NasopharyngitisInfections and infestations41/55327/278

Baseline characteristics

The full analysis set (FAS) included all randomised subjects.

Age, Continuous
Age, Continuous(years)IDeg ODIGlar ODTotal
Mean55.9 ± 9.756.6 ± 9.256.2 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)IDeg ODIGlar ODTotal
Female256146402
Male299132431
HbA1c
HbA1c(percentage of glycosylated haemoglobin)IDeg ODIGlar ODTotal
Mean8.3 ± 0.98.3 ± 0.88.3 ± 0.8
Fasting Plasma Glucose (FPG)
Fasting Plasma Glucose (FPG)(mmol/L)IDeg ODIGlar ODTotal
Mean9.4 ± 2.49.4 ± 2.59.4 ± 2.5
09

Study locations

81 sites
  • Novo Nordisk Investigational Site
    Anaheim, California 92801, United States
  • Novo Nordisk Investigational Site
    Lomita, California 90717, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90057, United States
  • Novo Nordisk Investigational Site
    Golden, Colorado 80401, United States
  • Novo Nordisk Investigational Site
    Clearwater, Florida 33765, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60607, United States
  • Novo Nordisk Investigational Site
    Crestview Hills, Kentucky 41017-3464, United States
  • Novo Nordisk Investigational Site
    Metairie, Louisiana 70002, United States
  • Novo Nordisk Investigational Site
    Troy, Michigan 48098, United States
  • Novo Nordisk Investigational Site
    Chesterfield, Missouri 63017, United States
  • Novo Nordisk Investigational Site
    Nashua, New Hampshire 03063, United States
  • Novo Nordisk Investigational Site
    Toms River, New Jersey 08755-8050, United States
  • Novo Nordisk Investigational Site
    Smithtown, New York 11787, United States
  • Novo Nordisk Investigational Site
    Simpsonville, South Carolina 29681, United States
  • Novo Nordisk Investigational Site
    Jackson, Tennessee 38305, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Newport News, Virginia 23606, United States
  • Novo Nordisk Investigational Site
    Kenosha, Wisconsin 53142, United States
  • Novo Nordisk Investigational Site
    São Paulo, Sao Paulo 01244-030, Brazil
  • Novo Nordisk Investigational Site
    Porto Alegre, 90035-170, Brazil
  • Novo Nordisk Investigational Site
    São Paulo, 04022-002, Brazil
  • Novo Nordisk Investigational Site
    Calgary, Alberta T2N 4L7, Canada
  • Novo Nordisk Investigational Site
    Burnaby, British Columbia V5G 1T4, Canada
  • Novo Nordisk Investigational Site
    Surrey, British Columbia V3S 2N6, Canada
  • Novo Nordisk Investigational Site
    Victoria, British Columbia V8V 4A1, Canada
  • Novo Nordisk Investigational Site
    Burlington, Ontario L7M 4Y1, Canada
  • Novo Nordisk Investigational Site
    London, Ontario N5W 6A2, Canada
  • Novo Nordisk Investigational Site
    London, Ontario N6P 1A9, Canada
  • Novo Nordisk Investigational Site
    Newmarket, Ontario L3Y 5G8, Canada
  • Novo Nordisk Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • Novo Nordisk Investigational Site
    Strathroy, Ontario N7G 1Y7, Canada
  • Novo Nordisk Investigational Site
    Trois Rivieres, Quebec G8T7A1, Canada
  • Novo Nordisk Investigational Site
    Quebec, G3K 2P8, Canada
  • Novo Nordisk Investigational Site
    Hefei, Anhui 230001, China
  • Novo Nordisk Investigational Site
    Beijing, Beijing 100029, China
  • Novo Nordisk Investigational Site
    Beijing, Beijing 100039, China
  • Novo Nordisk Investigational Site
    Beijing, Beijing 100191, China
  • Novo Nordisk Investigational Site
    Beijing, Beijing 100700, China
  • Novo Nordisk Investigational Site
    Beijing, Beijing 100730, China
  • Novo Nordisk Investigational Site
    Beijing, Beijing 100853, China
  • Novo Nordisk Investigational Site
    Chongqing, Chongqing 400010, China
  • Novo Nordisk Investigational Site
    Chongqing, Chongqing 400016, China
  • Novo Nordisk Investigational Site
    ChongQing, Chongqing 404000, China
  • Novo Nordisk Investigational Site
    Fuzhou, Fujian 350025, China
  • Novo Nordisk Investigational Site
    Guangzhou, Guangdong 510120, China
  • Novo Nordisk Investigational Site
    Nanning, Guangxi 530007, China
  • Novo Nordisk Investigational Site
    Guiyang, Guizhou 550004, China
  • Novo Nordisk Investigational Site
    Shijiazhuang, Hebei 050051, China
  • Novo Nordisk Investigational Site
    Shijiazhuang, Hebei 050082, China
  • Novo Nordisk Investigational Site
    Harbin, Heilongjiang 150086, China
  • Novo Nordisk Investigational Site
    Wuhan, Hubei 430030, China
  • Novo Nordisk Investigational Site
    Wuhan, Hubei 430034, China
  • Novo Nordisk Investigational Site
    Yueyang, Hunan 414000, China
  • Novo Nordisk Investigational Site
    Yangzhou, Jiangsu 225001, China
  • Novo Nordisk Investigational Site
    Zhenjiang, Jiangsu 212001, China
  • Novo Nordisk Investigational Site
    Nanchang, Jiangxi 330006, China
  • Novo Nordisk Investigational Site
    Changchun, Jilin 130041, China
  • Novo Nordisk Investigational Site
    Siping, Jilin 136000, China
  • Novo Nordisk Investigational Site
    Shenyang, Liaoning 110004, China
  • Novo Nordisk Investigational Site
    Shenyang, Liaoning 110021, China
  • Novo Nordisk Investigational Site
    Xi'an, Shaanxi 710032, China
  • Novo Nordisk Investigational Site
    Shanghai, Shanghai 200040, China
  • Novo Nordisk Investigational Site
    Shanghai, Shanghai 200072, China
  • Novo Nordisk Investigational Site
    Kunming, Yunnan 650101, China
  • Novo Nordisk Investigational Site
    Hangzhou, Zhejiang 310003, China
  • Novo Nordisk Investigational Site
    Wenzhou, Zhejiang 325000, China
  • Novo Nordisk Investigational Site
    Oradea, Bihor 410469, Romania
  • Novo Nordisk Investigational Site
    Bucharest, 020614, Romania
  • Novo Nordisk Investigational Site
    Buzau, 120203, Romania
  • Novo Nordisk Investigational Site
    Galati, 800578, Romania
  • Novo Nordisk Investigational Site
    Sibiu, 550176, Romania
  • Novo Nordisk Investigational Site
    George, Eastern Cape 6529, South Africa
  • Novo Nordisk Investigational Site
    Johannesburg, Gauteng 1812, South Africa
  • Novo Nordisk Investigational Site
    Johannesburg, Gauteng 2193, South Africa
  • Novo Nordisk Investigational Site
    Durban, KwaZulu-Natal 4001, South Africa
  • Novo Nordisk Investigational Site
    Durban, KwaZulu-Natal 4091, South Africa
  • Novo Nordisk Investigational Site
    Dnepropetrovsk, 49005, Ukraine
  • Novo Nordisk Investigational Site
    Dnepropetrovsk, 49038, Ukraine
  • Novo Nordisk Investigational Site
    Kiev, 04114, Ukraine
  • Novo Nordisk Investigational Site
    Mykolaiv, 54003, Ukraine
  • Novo Nordisk Investigational Site
    Vinnitsa, 21010, Ukraine
10

References and documents

Publications

  • Pan C, Gross JL, Yang W, Lv X, Sun L, Hansen CT, Xu H, Wagner R. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naive Patients with Type 2 Diabetes Mellitus. Drugs R D. 2016 Jun;16(2):239-49. doi: 10.1007/s40268-016-0134-z. PubMed 27098525 ↗
  • Mu YM, Guo LX, Li L, Li YM, Xu XJ, Li QM, Xu MT, Zhu LY, Yuan GY, Liu Y, Xu C, Wang ZJ, Shen FX, Luo Y, Liu JY, Li QF, Wang WH, Lai XY, Xu HF, Pan CY. [The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial]. Zhonghua Nei Ke Za Zhi. 2017 Sep 1;56(9):660-666. doi: 10.3760/cma.j.issn.0578-1426.2017.09.008. Chinese. PubMed 28870034 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in May 2014, 11 months.

Results were first posted in Jan 2016, 1 year 7 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 11 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2013
First posted
May 8, 2013
StartActual
Jun 2, 2013
Primary completionActual
May 15, 2014
CompletionActual
May 15, 2014
Results first posted
Jan 14, 2016
Last update
Apr 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01849289
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 8, 2013
Start date
Jun 2, 2013
Primary completion
May 15, 2014
Completion
May 15, 2014
Results posted
Jan 14, 2016
Last update
Apr 7, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin degludec · Insulin Glargine

Start the discussion